A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation

References

• Umanath K , Lewis JB . Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis . 2018;71(6):884–895. doi:10.1053/j.ajkd.2017.10.026 29398179
   PubMed Web of Science ®Google Scholar
• Wada J , Makino H . Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol . 2015;12(1):13–26. doi:10.1038/nrneph.2015.175 26568190
   PubMed Web of Science ®Google Scholar
• Nowak N , Skupien J , Smiles AM , et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int . 2018;93(5):1198–1206. doi:10.1016/j.kint.2017.11.024 29398132
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A . The role of the complement system in diabetic nephropathy. Nat Rev Nephrol . 2017;13(5):311–318. doi:10.1038/nrneph.2017.31 28262777
   PubMed Web of Science ®Google Scholar
• Qiu YY , Tang LQ . Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharmacol Res . 2016;114:251–264. doi:10.1016/j.phrs.2016.11.004 27826011
   PubMed Web of Science ®Google Scholar
• Lee HM , Kim JJ , Kim HJ , Shong M , Ku BJ , Jo EK . Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes . 2013;62(1):194–204. doi:10.2337/db12-0420 23086037
   PubMed Web of Science ®Google Scholar
• El-Horany HE , Abd-Ellatif RN , Watany M , Hafez YM , Okda HI . NLRP3 expression and urinary HSP72 in relation to biomarkers of inflammation and oxidative stress in diabetic nephropathy patients. IUBMB Life . 2017;69(8):623–630. doi:10.1002/iub.1645 28631886
   PubMed Web of Science ®Google Scholar
• Leemans JC , Kors L , Anders HJ , Florquin S . Pattern recognition receptors and the inflammasome in kidney disease. Nat Rev Nephrol . 2014;10(7):398–414. doi:10.1038/nrneph.2014.91 24890433
   PubMed Web of Science ®Google Scholar
• Lamkanfi M , Dixit Vishva M . Mechanisms and functions of inflammasomes. Cell . 2014;157(5):1013–1022. doi:10.1016/j.cell.2014.04.007 24855941
   PubMed Web of Science ®Google Scholar
• Lorenz G , Darisipudi MN , Anders H-J . Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dialysis Trans . 2014;29(1):41–48. doi:10.1093/ndt/gft332
   PubMed Web of Science ®Google Scholar
• Sakai N , Wada T . Revisiting inflammation in diabetic nephropathy: the role of the NLRP3 inflammasome in glomerular resident cells. Kidney Int . 2015;87(1):12–14. doi:10.1038/ki.2014.322 25549120
   PubMed Web of Science ®Google Scholar
• Shahzad K , Bock F , Dong W , et al. NLRP3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int . 2015;87(1):74–84. doi:10.1038/ki.2014.271 25075770
   PubMed Web of Science ®Google Scholar
• Coll RC , Robertson AA , Chae JJ , et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med . 2015;21(3):248–255. doi:10.1038/nm.3806 25686105
   PubMed Web of Science ®Google Scholar
• Salla M , Butler MS , Pelingon R , et al. Identification, synthesis, and biological evaluation of the major human metabolite of NLRP3 inflammasome inhibitor MCC950. ACS Med Chem Lett . 2016;7(12):1034–1038. doi:10.1021/acsmedchemlett.6b00198 27994733
   PubMed Web of Science ®Google Scholar
• Ludwig-Portugall I , Bartok E , Dhana E , et al. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int . 2016;90(3):525–539. doi:10.1016/j.kint.2016.03.035 27262364
   PubMed Web of Science ®Google Scholar
• Krishnan SM , Ling YH , Huuskes BM , et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage and dysfunction in salt-sensitive hypertension. Cardiovasc Res . 2018;115(4):776–87.
   Web of Science ®Google Scholar
• van der Heijden T , Kritikou E , Venema W , et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E–deficient mice—brief report. Arterioscler Thromb Vasc Biol . 2017;37(8):1457–1461. doi:10.1161/ATVBAHA.117.309575 28596375
   PubMed Web of Science ®Google Scholar
• Kim RY , Pinkerton JW , Essilfie AT , et al. Role for NLRP3 inflammasome-mediated, IL-1beta-dependent responses in severe, steroid-resistant Asthma. Am J Respir Crit Care Med . 2017;196(3):283–297. doi:10.1164/rccm.201609-1830OC 28252317
   PubMed Web of Science ®Google Scholar
• Hummel KP , Dickie MM , Coleman DL . Diabetes, a new mutation in the mouse. Science . 1966;153(3740):1127–1128.5918576
   PubMed Web of Science ®Google Scholar
• Sharma K , McCue P , Dunn SR . Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol . 2003;284(6):F11381144. doi:10.1152/ajprenal.00140.2002
   Web of Science ®Google Scholar
• Zhu X , Zhang C , Fan Q , et al. Inhibiting microRNA-503 and microRNA-181d with losartan ameliorates diabetic nephropathy in KKAy mice. Med Sci Monit . 2016;22:3902–3909.27770539
   PubMed Web of Science ®Google Scholar
• Yiu WH , Wong DW , Wu HJ , et al. Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress. Kidney Int . 2016;89(2):386–398. doi:10.1038/ki.2015.331 26536000
   PubMed Web of Science ®Google Scholar
• Canaud G , Bienaime F , Viau A , et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med . 2013;19(10):1288–1296. doi:10.1038/nm.3313 24056770
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF , Mora-Fernandez C . The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol . 2008;19(3):433–442. doi:10.1681/ASN.2007091048 18256353
   PubMed Web of Science ®Google Scholar
• Hickey FB , Martin F . Diabetic kidney disease and immune modulation. Curr Opin Pharmacol . 2013;13(4):602–612. doi:10.1016/j.coph.2013.05.002 23721739
   PubMed Web of Science ®Google Scholar
• Yuan J , Najafov A , Py BF . Roles of caspases in necrotic cell death. Cell . 2016;167(7):1693–1704. doi:10.1016/j.cell.2016.11.047 27984721
   PubMed Web of Science ®Google Scholar
• Risdon RA , Sloper JC , De Wardener HE . Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet . 1968;2(7564):363–366.4173786
   PubMed Web of Science ®Google Scholar
• Shi J , Zhao Y , Wang K , et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature . 2015;526(7575):660–665. doi:10.1038/nature15514 26375003
   PubMed Web of Science ®Google Scholar
• Jorgensen I , Miao EA . Pyroptotic cell death defends against intracellular pathogens. Immunol Rev . 2015;265(1):130–142. doi:10.1111/imr.12287 25879289
   PubMed Web of Science ®Google Scholar
• Yuan -Y-Y , Xie K-X , Wang S-L , Yuan L-W . Inflammatory caspase-related pyroptosis: mechanism, regulation and therapeutic potential for inflammatory bowel disease. Gastroenterol Rep . 2018;6(3):167–176. doi:10.1093/gastro/goy011
   Google Scholar
• Mridha AR , Wree A , Robertson AAB , et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol . 2017;66(5):1037–1046. doi:10.1016/j.jhep.2017.01.022 28167322
   PubMed Web of Science ®Google Scholar
• Qu J , Yuan Z , Wang G , Wang X , Li K . The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice. Int Immunopharmacol . 2019;70:147–155. doi:10.1016/j.intimp.2019.02.016 30802677
   PubMed Web of Science ®Google Scholar
• Zhang Y , Lv X , Hu Z , et al. Protection of MCC950 against high-glucose-induced human retinal endothelial cell dysfunction. Cell Death Dis . 2017;8(7):e2941. doi:10.1038/cddis.2017.518 28726778
   PubMed Web of Science ®Google Scholar
• Fu R , Guo C , Wang S , et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheum . 2017;69(8):1636–1646. doi:10.1002/art.40155
   PubMed Web of Science ®Google Scholar
• Pagtalunan ME , Miller PL , Jumping-Eagle S , et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest . 1997;99(2):342–348. doi:10.1172/JCI119163 9006003
   PubMed Web of Science ®Google Scholar
• Xu L , Fan Q , Wang X , et al. Ursolic acid improves podocyte injury caused by high glucose. Nephrol Dialysis Trans . 2017;32(8):1285–1293. doi:10.1093/ndt/gfv382
   PubMed Web of Science ®Google Scholar
• Greka A , Mundel P . Cell biology and pathology of podocytes. Annu Rev Physiol . 2012;74:299–323. doi:10.1146/annurev-physiol-020911-153238 22054238
   PubMed Web of Science ®Google Scholar
• Mollet G , Ratelade J , Boyer O , et al. Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome. J Am Soc Nephrol . 2009;20(10):2181–2189. doi:10.1681/ASN.2009040379 19713307
   PubMed Web of Science ®Google Scholar
• Mundel P , Shankland SJ . Podocyte biology and response to injury. J Am Soc Nephrol . 2002;13(12):3005–3015.12444221
   PubMed Web of Science ®Google Scholar
• Huber TB , Benzing T . The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens . 2005;14(3):211–216.15821412
   PubMed Web of Science ®Google Scholar
• Meng XM , Nikolic-Paterson DJ , Lan HY . Inflammatory processes in renal fibrosis. Nat Rev Nephrol . 2014;10(9):493–503. doi:10.1038/nrneph.2014.114 24981817
   PubMed Web of Science ®Google Scholar
• Wang E-M , Fan Q-L , Yue Y , Xu L . Ursolic acid attenuates high glucose-mediated mesangial cell injury by inhibiting the phosphatidylinositol 3-Kinase/Akt/Mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Med Sci Monit . 2018;24:846–854.29428962
   PubMed Web of Science ®Google Scholar
• Vesey DA , Cheung C , Cuttle L , Endre Z , Gobe G , Johnson DW . Interleukin-1β stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-β-dependent mechanism. J Lab Clin Med . 2002;140(5):342–350. doi:10.1067/mlc.2002.128468 12434136
   PubMed Web of Science ®Google Scholar
• Ma X , Ding J , Min H , Wen Y , Gao Q . Protective role of low-dose TGF-β1 in early diabetic nephropathy induced by streptozotocin. Int Immunopharmacol . 2013;17(3):752–758. doi:10.1016/j.intimp.2013.08.023 24055008
   PubMed Web of Science ®Google Scholar
• Cheng H , Chen C , Wang S , Ding G , Shi M . The effects of urokinase-type plasminogen activator (uPA) on cell proliferation and phenotypic transformation of rat mesangial cells induced by high glucose. Diabetes Res Clin Pract . 2014;103(3):489–495. doi:10.1016/j.diabres.2013.11.016 24447806
   PubMed Web of Science ®Google Scholar
• Song S , Qiu D , Luo F , et al. Knockdown of NLRP3 alleviates high glucose or TGFB1-induced EMT in human renal tubular cells. J Mol Endocrinol . 2018;61(3):101–113. doi:10.1530/JME-18-0069 30307163
   PubMed Web of Science ®Google Scholar
• Kammoun HL , Allen TL , Henstridge DC , et al. Evidence against a role for NLRP3-driven islet inflammation in db/db mice. Mol Metab . 2018;10:66–73. doi:10.1016/j.molmet.2018.02.001 29478918
   PubMed Web of Science ®Google Scholar